公司资料
Incyte 股价、新闻与催化剂
- 股票代码:
- INCY
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- Wilmington, Delaware
股票表现
123.50 USD (+2.78%)
收盘价
最后更新: 2026年8月17日
18.4B USD
市值
股价为何变动
As of Aug 17, 2026, INCY closed up 2.78% at $123.50. No new same-company headline was identified in the current news window.
公司概览
业务概览
Incyte is a biopharmaceutical company focused on hematology, oncology, and inflammation. Its business combines a commercial base with a pipeline that continues to produce new opportunities in immunology and cancer.
所在地与行业分类
Headquartered in Wilmington, Delaware and listed on NASDAQ, Incyte is a U.S.-based biotech with meaningful global commercial and development exposure. It sits in specialty biopharma rather than general healthcare.
商业模式特征
The company generates value through marketed products, R&D, and pipeline expansion across oncology and inflammatory disease. Investors track revenue durability, new data, and whether the next wave of programs can keep replacing mature growth.
生物医药行业定位
Incyte is a well-established biotech name with enough commercial scale to soften pure binary risk, but it still reacts to clinical data and label expansion. It sits in a strong middle ground between mature pharma and high-volatility development biotech.
未来催化剂
- Incyte’s near-term catalysts are Opzelura growth, povorcitinib readouts, and any label-expansion or pipeline update in dermatology and oncology. That readout matters because it decides whether the asset is ready for a larger and more expensive development step. If the data come in cleanly, the market tends to give the broader platform behind the program more credit.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。